Lucid Diagnostics Files 8-K

TL;DR

Lucid Diagnostics filed an 8-K on Dec 20 for an event on Dec 19.

AI Summary

Lucid Diagnostics Inc. filed an 8-K on December 20, 2024, reporting an event on December 19, 2024. The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'. The company's principal executive offices are located at 360 Madison Avenue, New York, NY.

Why It Matters

This 8-K filing indicates a significant event or update from Lucid Diagnostics Inc., requiring disclosure to investors and the public.

Risk Assessment

Risk Level: low — This filing is a standard procedural disclosure and does not inherently indicate significant risk.

Key Players & Entities

• Lucid Diagnostics Inc. (company) — Registrant
• December 19, 2024 (date) — Earliest event reported
• December 20, 2024 (date) — Filing date
• 360 Madison Avenue, 25th Floor, New York, New York 10017 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, Par Value $0.001 Per Share LUCD The Nasdaq Stock Mar
• $1 — mon stock had been below the minimum of $1 per share required for continued listin

Filing Documents

• form8-k.htm (8-K) — 40KB
• 0001493152-24-051061.txt ( ) — 213KB
• lucd-20241219.xsd (EX-101.SCH) — 3KB
• lucd-20241219_lab.xml (EX-101.LAB) — 33KB
• lucd-20241219_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. On December 19, 2024, Lucid Diagnostics Inc. (the " Company ") received a letter from the Listing Qualifications department of The Nasdaq Stock Market (" Nasdaq ") notifying the Company that it would be afforded an additional 180 calendar days (or until June 16, 2025) to regain compliance with Nasdaq's minimum bid price requirement. As previously disclosed, on June 21, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications department stating that, for the prior 30 consecutive business days (through June 20, 2024), the closing bid price of the Company's common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The initial notification letter stated that the Company would be afforded 180 calendar days (until December 18, 2024) to regain compliance, and that the Company could be eligible for additional time. Although the Company did not regain compliance within the initial 180 calendar day period, Nasdaq determined that the Company was eligible for the additional 180 calendar day period to regain compliance. In order to regain compliance, the closing bid price of the Company's common stock must be at least $1 per share for a minimum of ten consecutive business days during the additional 180 calendar day period. The Company intends to consider all available options to regain compliance with the Nasdaq listing standards. The Nasdaq notification has no effect at this time on the listing of the Company's common stock, which will continue to trade uninterrupted under the symbol "LUCD."

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 20, 2024 LUCID DIAGNOSTICS INC. By: /s/ Dennis McGrath Dennis McGrath Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR